Unknown

Dataset Information

0

WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP).


ABSTRACT: Wiskott-Aldrich syndrome protein (WASP) is in a complex with WASP-interacting protein (WIP). WASP levels, but not mRNA levels, were severely diminished in T cells from WIP(-/-) mice and were increased by introduction of WIP in these cells. The WASP binding domain of WIP was shown to protect WASP from degradation by calpain in vitro. Treatment with the proteasome inhibitors MG132 and bortezomib increased WASP levels in T cells from WIP(-/-) mice and in T and B lymphocytes from two WAS patients with missense mutations (R86H and T45M) that disrupt WIP binding. The calpain inhibitor calpeptin increased WASP levels in activated T and B cells from the WASP patients, but not in primary T cells from the patients or from WIP(-/-) mice. Despite its ability to increase WASP levels proteasome inhibition did not correct the impaired IL-2 gene expression and low F-actin content in T cells from the R86H WAS patient. These results demonstrate that WIP stabilizes WASP and suggest that it may also be important for its function.

SUBMITTER: de la Fuente MA 

PROVIDER: S-EPMC1783416 | biostudies-literature | 2007 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP).

de la Fuente Miguel A MA   Sasahara Yoji Y   Calamito Marco M   Antón Inés M IM   Elkhal Abdallah A   Gallego Maria D MD   Suresh Koduru K   Siminovitch Katherine K   Ochs Hans D HD   Anderson Kenneth C KC   Rosen Fred S FS   Geha Raif S RS   Ramesh Narayanaswamy N  

Proceedings of the National Academy of Sciences of the United States of America 20070109 3


Wiskott-Aldrich syndrome protein (WASP) is in a complex with WASP-interacting protein (WIP). WASP levels, but not mRNA levels, were severely diminished in T cells from WIP(-/-) mice and were increased by introduction of WIP in these cells. The WASP binding domain of WIP was shown to protect WASP from degradation by calpain in vitro. Treatment with the proteasome inhibitors MG132 and bortezomib increased WASP levels in T cells from WIP(-/-) mice and in T and B lymphocytes from two WAS patients wi  ...[more]

Similar Datasets

| S-EPMC2000553 | biostudies-literature
| S-EPMC25088 | biostudies-literature
| S-EPMC6556382 | biostudies-literature
| S-EPMC3350364 | biostudies-other
| S-EPMC2770938 | biostudies-literature
| S-EPMC7953068 | biostudies-literature
| S-EPMC5816175 | biostudies-literature
| S-EPMC10972719 | biostudies-literature
| S-EPMC1283820 | biostudies-literature
| S-EPMC2196001 | biostudies-literature